FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 216 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival... March 22, 2022 Lo que deben saber las personas con cáncer de mama y... January 4, 2024 Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically... March 23, 2023 Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination... December 9, 2020 Load more HOT NEWS Καρκίνος Δέρματος Adding Atezolizumab to Cabozantinib Fails to Improve Clinical Outcomes and Increases... Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and... News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and...
